无创检查可基于肝脏相关事件风险准确分层NAFLD患者
多中心队列纳入1057例NAFLD患者(594例有基线肝活检),评估FIB4和VCTE对肝脏相关事件(LRE)的预测准确性。FIB4与VCTE的Harrell C指数均>0.80,VCTE与肝活检纤维化分期无显著差异,FIB4-VCTE阶梯算法可准确分层LRE风险。
要点
- FIB4与VCTE预测LRE的Harrell C指数均>0.80。
- 活检亚组中VCTE与肝活检纤维化分期的C指数无显著差异。
- FIB4≥1.30后VCTE>12.0 kPa者LRE风险显著升高(aHR 12.4)。
核心结论
- VCTE和FIB4可基于LRE风险准确分层NAFLD患者。
- 这些无创检查可作为肝活检的替代方法,用于识别需要专科管理的患者。
研究设计与样本
- 多中心队列纳入1057例NAFLD患者,均有基线FIB4和VCTE,其中594例同时有基线肝活检。
- 随访主要结局为LRE,即肝硬化并发症和/或肝细胞癌的复合终点。
- 采用Harrell C指数评估区分能力。
主要发现
- FIB4与VCTE预测LRE的Harrell C指数分别为0.817(0.768-0.866)与0.878(0.835-0.921),p=0.059。
- 活检亚组中,组织学纤维化分期与VCTE的Harrell C指数分别为0.932(0.910-0.955)与0.881(0.832-0.931),p=0.164,两者均显著优于FIB4。
- FIB4和VCTE在全队列中均为LRE的独立预测因素。
- 与FIB4<1.30者相比,FIB4≥1.30且VCTE<8.0 kPa者LRE风险相似(aHR 1.3;95%CI 0.3-6.8)。
- 与FIB4<1.30者相比,FIB4≥1.30且VCTE 8.0-12.0 kPa者LRE风险显著升高(aHR 3.8;95%CI 1.3-10.9),VCTE>12.0 kPa者更高(aHR 12.4;95%CI 5.1-30.2)。
关键数值与推荐
- FIB4-VCTE阶梯算法:FIB4<1.30为低风险参照组。
- FIB4≥1.30后VCTE<8.0 kPa者LRE风险与参照组相似(aHR 1.3;95%CI 0.3-6.8)。
- FIB4≥1.30后VCTE 8.0-12.0 kPa者LRE风险显著升高(aHR 3.8;95%CI 1.3-10.9)。
- FIB4≥1.30后VCTE>12.0 kPa者LRE风险进一步显著升高(aHR 12.4;95%CI 5.1-30.2)。
临床怎么用
- 作者认为,VCTE和FIB4是肝活检的替代方法,可用于识别需要专科管理的NAFLD患者。
- 作者认为,这些结果支持使用无创肝纤维化检查替代肝活检来管理NAFLD患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Previous studies on the prognostic significance of non-invasive liver fibrosis tests in non-alcoholic fatty liver disease (NAFLD) lack direct comparison to liver biopsy. We aimed to evaluate the prognostic accuracy of fibrosis-4 (FIB4) and vibration-controlled transient elastography (VCTE), compared to liver biopsy, for the prediction of liver-related events (LREs) in NAFLD. METHODS: A total of 1,057 patients with NAFLD and baseline FIB4 and VCTE were included in a multicenter cohort. Of these patients, 594 also had a baseline liver biopsy. The main study outcome during follow-up was occurrence of LREs, a composite endpoint combining cirrhosis complications and/or hepatocellular carcinoma. Discriminative ability was evaluated using Harrell's C-index. RESULTS: FIB4 and VCTE showed good accuracy for the prediction of LREs, with Harrell's C-indexes >0.80 (0.817 [0.768-0.866] vs. 0.878 [0.835-0.921], respectively, p = 0.059). In the biopsy subgroup, Harrell's C-indexes of histological fibrosis staging and VCTE were not significantly different (0.932 [0.910-0.955] vs. 0.881 [0.832-0.931], respectively, p = 0.164), while both significantly outperformed FIB4 for the prediction of LREs. FIB4 and VCTE were independent predictors of LREs in the whole study cohort. The stepwise FIB4-VCTE algorithm accurately stratified the risk of LREs: compared to patients with "FIB4 <1.30", those with "FIB4 ≥1.30 then VCTE <8.0 kPa" had similar risk of LREs (adjusted hazard ratio [aHR] 1.3; 95% CI 0.3-6.8), whereas the risk of LREs significantly increased in patients with "FIB4 ≥1.30 then VCTE 8.0-12.0 kPa" (aHR 3.8; 95% CI 1.3-10.9), and even more for those with "FIB4 ≥1.30 then VCTE >12.0 kPa" (aHR 12.4; 95% CI 5.1-30.2). CONCLUSION: VCTE and FIB4 accurately stratify patients with NAFLD based on their risk of LREs. These non-invasive tests are alternatives to liver biopsy for the identification of patients in need of specialized management. LAY SUMMARY: The amount of fibrosis in the liver is closely associated with the risk of liver-related complications in non-alcoholic fatty liver disease (NAFLD). Liver biopsy currently remains the reference standard for the evaluation of fibrosis, but its application is limited by its invasiveness. Therefore, we evaluated the ability of non-invasive liver fibrosis tests to predict liver-related complications in NAFLD. Our results show that the blood test FIB4 and transient elastography stratify the risk of liver-related complications in NAFLD, and that transient elastography has similar prognostic accuracy as liver biopsy. These results support the use of non-invasive liver fibrosis tests instead of liver biopsy for the management of patients with NAFLD.
引用
- Boursier J, Hagström H, Ekstedt M, et al. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. J Hepatol. 2022. PMID: 35063601. doi:10.1016/j.jhep.2021.12.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。